News
Researchers bag US$50m NIH grant to study impact of environmental factors on pregnancy
Researchers from the University of Pennsylvania, Children’s Hospital of Philadelphia and Penn Medicine have received a US$50m grant from the National Institutes of Health to study the impact of environmental factors on pregnancy and children’s health.
The research programme is part of the NIH’s Environmental influences on Child Health Outcomes (ECHO) Program, which funds research to uncover how environmental exposures during preconception, pregnancy and early life affect children’s long-term health.
Patients will be enrolled at Penn Medicine while pregnant, then the infants will be followed into childhood via teams at COP.
Sunni L. Mumford, co-lead investigator and co-director of the Women’s Health Clinical Research Center and deputy director of epidemiology in the Perelman School of Medicine at the University of Pennsylvania, said: “At Penn and CHOP, we serve a diverse population including a group of patients who are underrepresented in other pregnancy and paediatric cohorts in the United States: patients who are Black and insured by Medicaid.
“It is so important to understand how environmental toxicants and beneficial exposures shape the health of Philadelphia’s children.
“By contributing to the national ECHO Cohort, our research will benefit not only our institutional and neighborhood communities but also communities across the country.”
Heather Burris, an attending neonatologist at CHOP and co-lead investigator of the Penn-CHOP study site, said: “We are thrilled to have been chosen as an ECHO Cohort Study Site and for the opportunity to contribute to this important project, which will improve our understanding of the ways the local environment affects our children’s health.
“We know that communities are not equally exposed to environmental toxicants, and we also know that health inequities and disparities are an ongoing public health problem.
“This project will help us shed light on the extent to which the health inequities we see in our patient population are related to neighbourhood environmental exposures.”
Prior research has shown that Black infants are twice as likely to die compared to white infants, primarily due to adverse pregnancy outcomes like preterm birth.
Although extensive efforts have been taken to prevent preterm birth and improve child health, inequities across the population persist, and researchers still do not fully understand how and to what extent specific factors in the environment contribute to these ongoing problems.
To fill this gap, the CHOP and Penn researchers aim to recruit up to 2,500 pregnant people, partners, and offspring over a period of three years into the ECHO Cohort, a nationwide pool of research subjects managed by institutions across the country.
The aim across the ECHO cohort is to establish a group of pregnant people and children from different types of neighbourhoods and communities, which will allow investigators to explore questions about the impact of early environmental exposures on child health at a large and diverse scale.
Over the seven-year period of the grant, the researchers plan to evaluate the impact on maternal-child health of specific “macroenvironmental” factors – that is, factors related to the neighbourhood environment, from those that promote health, like greenspace and walkability, to those that detract from health, like pollution, neighbourhood violence and extreme temperatures.
The team want to identify modifiable factors that influence the risks of abnormal foetal growth, preterm birth, obesity, asthma, and neurodevelopmental delays, as well as whether modifying these factors may improve overall racial health disparities.
The researchers also plan to identify beneficial “microenvironmental” factors – the individual behaviours of a pregnant person, such as diet, physical activity, and sleep, which could potentially close the gap in child health outcomes.
Although prior research has looked at the health impacts of macro- and microenvironmental factors individually, no studies have explored the interplay between the two and the impact they could have on maternal-child health.
Sara B. DeMauro, an attending neonatologist at CHOP and co-lead investigator of the Penn-CHOP study site, said: “The culture of clinical research, excellent scientific environment, and diverse population makes Penn and CHOP the ideal place to innovate in the field of maternal-child health equity.
“The Penn-CHOP ECHO Study Site now joins the Philadelphia Regional Center for Children’s Environmental Health, the Penn Center of Excellence in Environmental Toxicology (CEET), and the CHOP Center for Health Equity in leading the way to improve children’s health, support environmental justice, and reduce health disparities.”
Insight
Topical HRT protects bone density in women with period loss – study
Transdermal HRT best protects bone density in women with functional hypothalamic amenorrhoea, a condition that stops periods, a review of trials has found.
The meta-analysis pooled randomised clinical trials involving 692 participants and found transdermal hormone replacement therapy and teriparatide increased bone mineral density by between 2 and 13 per cent.
Functional hypothalamic amenorrhoea can follow anorexia or intense exercise. Bone mineral density measures bone strength and the amount of mineral in bone.
Around half of women with the condition have low bone mineral density, compared with about 1 per cent of healthy women, and their fracture risk is up to seven times higher.
The research was conducted by scientists at Imperial College London and Imperial College Healthcare NHS Trust.
Professor Alexander Comninos, senior author of the study and consultant endocrinologist at the trust, said: “Bone density is lost very rapidly in FHA and so addressing bone health early is very important to reduce the lifelong risk of fractures.
“Our study provides much needed comparisons of all the available treatments from all available studies.
“Clearly the best treatment is to restore normal menstrual cycles and therefore oestrogen levels through various psychological, nutritional or exercise interventions – but that is not always possible.
“The foundation for bone health is good calcium and vitamin D intake (through diet and/or supplements) but we have additional treatments that are more effective.”
When FHA is diagnosed, clinicians first try to restore periods through lifestyle measures, including psychological and dietary support, but these can fail. Guidelines then recommend giving oestrogen, though the best form was unclear.
The team reviewed all prior randomised trials comparing therapies, including oral and transdermal oestrogen, and also assessed teriparatide, a prescription bone-building drug used for severe osteoporosis.
They found no significant benefit for oral contraceptive pills or oral hormone therapy.
A recent UK audit reported that about a quarter of women with anorexia-related FHA are prescribed the oral contraceptive pill for bone loss; the study suggests using transdermal therapy instead.
Comninos said: “Our goal is simple: to help women receive the right treatment sooner and to protect their bone health in the long-term.
“We hope this study provides clinicians with better evidence to choose transdermal oestrogen when prescribing oestrogen and so inform future practice guidelines.
“Right now, millions of women with FHA may not be receiving the best treatments for their bone health.”
Insight
AI cuts interval breast cancers in Swedish trial
Mental health
Fear of ageing may age women faster, study suggests
-
Features4 weeks agoWomen’s health enters a new era – the trends shaping femtech in 2026
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Features4 weeks agoBest menopause apps and products for 2026
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoHigher maternal blood pressure increases risk of pregnancy complications, study finds
-
Entrepreneur4 weeks agoXella Health closes US$3.7 million in pre-seed financing
-
Insight4 weeks agoInside the first wave of speakers confirmed for Women’s Health Week USA 2026







241 Comments